Avalo Therapeutics Stock: BofA Sees 156% Upside with New Buy Rating
Strong analyst support for abdakibart in hidradenitis suppurativa as Avalo advances to Phase 3.
/ 4 items
#AVTX↓
Avalo Therapeutics Reports Strong Phase 2 Results for Abdakibart in Hidradenitis Suppurativa – Ready to Advance to Phase 3
Avalo’s abdakibart showed strong results in reducing HS symptoms in a Phase 2 trial, with a favorable safety profile and better outcomes than placebo.
Wolfe Research Initiates Coverage on Palisade Bio and Avalo Therapeutics with Strong Buy Calls
Wolfe Research: PALI “Outperform” ($7) eyes 2027 ulcerative colitis trial; AVTX “Outperform” ($48) waits May LOTUS Phase 2 readout.
Guggenheim Gives Avalo Therapeutics a Buy Rating on AVTX-009
Guggenheim starts coverage of Avalo Therapeutics with a Buy rating, highlighting AVTX-009 as a promising IL-1beta treatment for Hidradenitis suppurativa (HS) and $2.1B peak sales potential.